Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1989 Jul;28(1):61–69. doi: 10.1111/j.1365-2125.1989.tb03506.x

The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa.

D R Robertson 1, N D Wood 1, H Everest 1, K Monks 1, D G Waller 1, A G Renwick 1, C F George 1
PMCID: PMC1379971  PMID: 2775615

Abstract

1. The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa was investigated in young and elderly healthy volunteers. 2. The plasma clearance of levodopa following intravenous administration of 50 mg was 14.2 +/- 2.8 (s.d.) ml min-1 kg-1 in the elderly compared with 23.4 +/- 4.1 ml min-1 kg-1 in the young (P less than 0.01) which resulted in a 49% greater area under the plasma concentration-time curve (AUC) in the older subjects (P less than 0.01). The volume of distribution (Vss) was lower in the elderly (1.01 +/- 0.29 l kg-1) than in the young (1.65 +/- 0.39 l kg-1) (P less than 0.002). 3. Following oral administration of 250 mg of levodopa the AUC was 2512 +/- 588 ng ml-1h in the elderly compared with 1056 +/- 282 ng ml-1h in the young (P less than 0.002). Cmax was also significantly greater in the elderly (P less than 0.05). The bioavailability of levodopa was significantly greater in the elderly (0.63 +/- 0.12 compared with 0.41 +/- 0.16, P less than 0.01). 4. In the presence of carbidopa, the plasma clearance of intravenous levodopa (50 mg) was reduced in both age groups but remained lower in the elderly (5.8 +/- 0.9 ml min-1 kg-1 compared with 9.3 +/- 1.0 ml min-1 kg-1; P less than 0.01). This resulted in a 54% greater AUC in the older subjects (P less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
61

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abrams W. B., Coutinho C. B., Leon A. S., Spiegel H. E. Absorption and metabolism of levodopa. JAMA. 1971 Dec 27;218(13):1912–1914. [PubMed] [Google Scholar]
  2. Awapara J., Saine S. Fluctuations in DOPA decarboxylase activity with age. J Neurochem. 1975 Apr;24(4):817–818. [PubMed] [Google Scholar]
  3. BENDER A. D. THE EFFECT OF INCREASING AGE ON THE DISTRIBUTION OF PERIPHERAL BLOOD FLOW IN MAN. J Am Geriatr Soc. 1965 Mar;13:192–198. doi: 10.1111/j.1532-5415.1965.tb02665.x. [DOI] [PubMed] [Google Scholar]
  4. Bender A. D. Effect of age on intestinal absorption: implications for drug absorption in the elderly. J Am Geriatr Soc. 1968 Dec;16(12):1331–1339. doi: 10.1111/j.1532-5415.1968.tb02776.x. [DOI] [PubMed] [Google Scholar]
  5. Broe G. A., Caird F. I. Levodopa for parkinsonism in elderly and demented patients. Med J Aust. 1973 Mar 31;1(13):630–635. doi: 10.5694/j.1326-5377.1973.tb110594.x. [DOI] [PubMed] [Google Scholar]
  6. Durnin J. V., Rahaman M. M. The assessment of the amount of fat in the human body from measurements of skinfold thickness. Br J Nutr. 1967 Aug;21(3):681–689. doi: 10.1079/bjn19670070. [DOI] [PubMed] [Google Scholar]
  7. Evans M. A., Broe G. A., Triggs E. J., Cheung M., Creasey H., Paull P. D. Gastric emptying rate and the systemic availability of levodopa in the elderly parkinsonian patient. Neurology. 1981 Oct;31(10):1288–1294. doi: 10.1212/wnl.31.10.1288. [DOI] [PubMed] [Google Scholar]
  8. Evans M. A., Triggs E. J., Broe G. A., Saines N. Systemic activity of orally administered L-dopa in the elderly Parkinson patient. Eur J Clin Pharmacol. 1980;17(3):215–221. doi: 10.1007/BF00561903. [DOI] [PubMed] [Google Scholar]
  9. Forbes G. B., Reina J. C. Adult lean body mass declines with age: some longitudinal observations. Metabolism. 1970 Sep;19(9):653–663. doi: 10.1016/0026-0495(70)90062-4. [DOI] [PubMed] [Google Scholar]
  10. Freed C. R., Asmus P. A. Brain tissue and plasma assay of L-DOPA and alpha-methyldopa metabolites by high performance liquid chromatography with electrochemical detection. J Neurochem. 1979 Jan;32(1):163–168. doi: 10.1111/j.1471-4159.1979.tb04523.x. [DOI] [PubMed] [Google Scholar]
  11. George C. F. Drug kinetics and hepatic blood flow. Clin Pharmacokinet. 1979 Nov-Dec;4(6):433–448. doi: 10.2165/00003088-197904060-00003. [DOI] [PubMed] [Google Scholar]
  12. Godwin-Austen R. B., Frears C. C., Bergmann S. Incidence of side effects from levodopa during the introduction of treatment. Br Med J. 1971 Jan 30;1(5743):267–268. doi: 10.1136/bmj.1.5743.267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Grad B., Wener J., Rosenberg G., Wener S. W. Effects of levodopa therapy in patients with Parkinson's disease: statistical evidence for reduced tolerance to levodopa in the elderly. J Am Geriatr Soc. 1974 Nov;22(11):489–494. doi: 10.1111/j.1532-5415.1974.tb05836.x. [DOI] [PubMed] [Google Scholar]
  14. Hinterberger H., Andrews C. J. Catecholamine metabolism during oral administration of levodopa. Arch Neurol. 1972 Mar;26(3):245–252. doi: 10.1001/archneur.1972.00490090071005. [DOI] [PubMed] [Google Scholar]
  15. Iwamoto K., Watanabe J., Atsumi F. Age dependence in capacity-limited jejunal decarboxylation of levodopa in rats. Biochem Pharmacol. 1987 Jul 1;36(13):2151–2155. doi: 10.1016/0006-2952(87)90144-4. [DOI] [PubMed] [Google Scholar]
  16. Kaakkola S., Männistö P. T., Nissinen E., Vuorela A., Mäntylä R. The effect of an increased ratio of carbidopa to levodopa on the pharmacokinetics of levodopa. Acta Neurol Scand. 1985 Oct;72(4):385–391. doi: 10.1111/j.1600-0404.1985.tb00888.x. [DOI] [PubMed] [Google Scholar]
  17. McAllister R. G., Jr Age-related changes in drug handling in man. Am J Cardiol. 1986 Feb 12;57(5):59C–62C. doi: 10.1016/0002-9149(86)91028-3. [DOI] [PubMed] [Google Scholar]
  18. Nutt J. G., Fellman J. H. Pharmacokinetics of levodopa. Clin Neuropharmacol. 1984;7(1):35–49. doi: 10.1097/00002826-198403000-00002. [DOI] [PubMed] [Google Scholar]
  19. Nutt J. G., Woodward W. R., Anderson J. L. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism. Ann Neurol. 1985 Nov;18(5):537–543. doi: 10.1002/ana.410180505. [DOI] [PubMed] [Google Scholar]
  20. Pinder R. M., Brogden R. N., Sawyer P. R., Speight T. M., Avery G. S. Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism. Drugs. 1976;11(5):329–377. doi: 10.2165/00003495-197611050-00001. [DOI] [PubMed] [Google Scholar]
  21. Rawlins M. D., James O. F., Williams F. M., Wynne H., Woodhouse K. W. Age and the metabolism of drugs. Q J Med. 1987 Jul;64(243):545–547. [PubMed] [Google Scholar]
  22. Romero J. A., Lytle L. D., Ordonez L. A., Wurtman R. J. Effects of L-dopa administration of the concentrations of dopa, dopamine and norepinephrine in various rat tissues. J Pharmacol Exp Ther. 1973 Jan;184(1):67–72. [PubMed] [Google Scholar]
  23. Sasahara K., Nitanai T., Habara T., Kojima T., Kawahara Y., Morioka T., Nakajima E. Dosage form design for improvement of bioavailability of levodopa IV: Possible causes of low bioavailability of oral levodopa in dogs. J Pharm Sci. 1981 Jul;70(7):730–733. doi: 10.1002/jps.2600700705. [DOI] [PubMed] [Google Scholar]
  24. Turnbull C. J., Aitken J. A. Diagnosis and management of parkinsonism in the elderly. Age Ageing. 1983 Nov;12(4):309–316. doi: 10.1093/ageing/12.4.309. [DOI] [PubMed] [Google Scholar]
  25. Wade D. N., Mearrick P. T., Birkett D. J., Morris J. Variability of L-dopa absorption in man. Aust N Z J Med. 1974 Apr;4(2):138–143. doi: 10.1111/j.1445-5994.1974.tb03162.x. [DOI] [PubMed] [Google Scholar]
  26. White N. J., Barnes T. R. Senile parkinsonism, a study of current treatment. Age Ageing. 1981 May;10(2):81–86. doi: 10.1093/ageing/10.2.81. [DOI] [PubMed] [Google Scholar]
  27. Wilkinson G. R., Shand D. G. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975 Oct;18(4):377–390. doi: 10.1002/cpt1975184377. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES